These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 6375559

  • 1. Ceftazidime nephrotoxicity in rats.
    Luft FC, Visscher DW, Nierste DM, Blase DK, Walker NA, Aronoff GR.
    Antimicrob Agents Chemother; 1984 Apr; 25(4):513-4. PubMed ID: 6375559
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Enzymuria: a parameter for the assessment of potential nephrotoxicity of cephalosporins.
    Mondorf AW, Scherberich JE, Heinert G, Schoeppe W.
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():251-4. PubMed ID: 6137472
    [Abstract] [Full Text] [Related]

  • 4. Cephalosporin-induced nephrotoxicity: does it exist?
    Zhanel GG.
    DICP; 1990 Mar; 24(3):262-5. PubMed ID: 2180220
    [Abstract] [Full Text] [Related]

  • 5. Assessment of the nephrotoxic potential of ceftazidime and a ceftazidime/tobramycin combination in volunteers.
    Mondorf AW, Heynold FT, Scherberich JE, Hess H, Schoeppe W.
    Infection; 1983 Mar; 11 Suppl 1():S57-62. PubMed ID: 6131873
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Influence of daptomycin on staphylococcal abscesses and experimental tobramycin nephrotoxicity.
    Wood CA, Finkbeiner HC, Kohlhepp SJ, Kohnen PW, Gilbert DN.
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1280-5. PubMed ID: 2552905
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nephrotoxicity of aminoglycosides and cephalosporins in combination.
    Rankin GO, Sutherland CH.
    Adverse Drug React Acute Poisoning Rev; 1989 Aug; 8(2):73-88. PubMed ID: 2672726
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia.
    Mandell LA, Nicolle LE, Ronald AR, Landis SJ, Duperval R, Harding GK, Robson HG, Feld R, Vincelette J, Fong I.
    J Antimicrob Chemother; 1987 Jul; 20(1):95-107. PubMed ID: 3305464
    [Abstract] [Full Text] [Related]

  • 17. Nephrotoxic potential of first-, second-, and third-generation cephalosporins.
    Cojocel C, Göttsche U, Tölle KL, Baumann K.
    Arch Toxicol; 1988 Jul; 62(6):458-64. PubMed ID: 3250376
    [Abstract] [Full Text] [Related]

  • 18. Safety evaluation of meropenem in animals: studies on the kidney.
    Topham JC, Murgatroyd LB, Jones DV, Goonetilleke UR, Wright J.
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():287-306. PubMed ID: 2681127
    [Abstract] [Full Text] [Related]

  • 19. Influence of dosage regimen on experimental tobramycin nephrotoxicity. A biochemical approach.
    Olier B, Viotte G, Morin JP, Fillastre JP.
    Chemotherapy; 1983 Sep; 29(6):385-94. PubMed ID: 6653171
    [Abstract] [Full Text] [Related]

  • 20. Ceftriaxone protects against tobramycin nephrotoxicity.
    Beauchamp D, Thériault G, Grenier L, Gourde P, Perron S, Bergeron Y, Fontaine L, Bergeron MG.
    Antimicrob Agents Chemother; 1994 Apr; 38(4):750-6. PubMed ID: 8031041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.